Overview
- Arife is formally registered in Mainz as a European stock corporation with €120,000 in entered share capital and Michael Maximilian Kring listed as a board member.
- The central point of contention is which foundational mRNA patents and technologies BioNTech will transfer or license to Arife, and participants say those talks have proven harder and slower than expected.
- BioNTech currently retains the relevant patents and had proposed contributing certain rights in return for a minority stake in Arife plus milestone payments and license fees, but no binding agreement has been signed.
- The founders, Uğur Şahin and Özlem Türeci, plan to move into Arife’s leadership once their BioNTech contracts expire by the end of 2026 and aim to recruit a low three‑digit research team drawn largely from trusted colleagues.
- If negotiations fail the separation could reshape where early‑stage mRNA research is developed and how both companies share future clinical upside, while Şahin and Türeci would remain financially linked to BioNTech as shareholders.